View Past PerformanceAinos バランスシートの健全性財務の健全性 基準チェック /26Ainosの総株主資本は$7.6M 、総負債は$11.0Mで、負債比率は145.5%となります。総資産と総負債はそれぞれ$20.9Mと$13.3Mです。主要情報145.45%負債資本比率US$11.00m負債インタレスト・カバレッジ・レシオn/a現金US$417.35kエクイティUS$7.56m負債合計US$13.31m総資産US$20.87m財務の健全性に関する最新情報Ainos (NASDAQ:AIMD) Has Debt But No Earnings; Should You Worry?Dec 12Ainos (NASDAQ:AIMD) Is Carrying A Fair Bit Of DebtAug 29Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)Jul 20We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of DebtMar 10Ainos Regains Compliance with Nasdaq Minimum Bid Price RequirementJan 02Here's Why Ainos (NASDAQ:AIMD) Can Afford Some DebtAug 28すべての更新を表示Recent updatesNew major risk - Market cap size Feb 18Ainos (NASDAQ:AIMD) Has Debt But No Earnings; Should You Worry?Dec 12New major risk - Market cap size Nov 20Ainos, Inc., Annual General Meeting, Nov 07, 2025Oct 03Ainos (NASDAQ:AIMD) Is Carrying A Fair Bit Of DebtAug 29First quarter 2025 earnings released: US$0.21 loss per share (vs US$0.57 loss in 1Q 2024) May 16Full year 2024 earnings released: US$1.56 loss per share (vs US$3.36 loss in FY 2023) Mar 09Ainos, Inc. Announces Institutional Review Board Approval for Sjögren’S Syndrome Clinical StudyNov 12Third quarter 2024 earnings released: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023) Nov 08Ainos, Inc. Advances Healthcare and Industrial Innovations with AI Nose and VELDONA TechnologiesOct 08Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for HIV-Oral Warts Clinical TrialSep 26Ainos Announces Plan to Initiate Taiwan Clinical Study for Veldona as Potential Treatment of Oral Warts in HIV-Positive PatientsSep 18Ainos, Inc. Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing SafetyAug 20Ainos, Inc., Annual General Meeting, Sep 27, 2024Aug 16Second quarter 2024 earnings released: US$0.49 loss per share (vs US$0.58 loss in 2Q 2023) Aug 06Ainos, Inc Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS DrugJul 24Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)Jul 20Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDAJun 15Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential MarketMay 16First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.63 loss in 1Q 2023) May 15New major risk - Shareholder dilution May 08We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of DebtMar 10Full year 2023 earnings released: US$3.36 loss per share (vs US$5.14 loss in FY 2022) Mar 10Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 SymptomsFeb 05New minor risk - Shareholder dilution Jan 30Ainos Regains Compliance with Nasdaq Minimum Bid Price RequirementJan 02Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of SmellDec 26Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate SecretaryDec 23Less than half of directors are independent Dec 16Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDANov 22Ainos, Inc., Annual General Meeting, Dec 08, 2023Oct 29Here's Why Ainos (NASDAQ:AIMD) Can Afford Some DebtAug 28Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.20 loss in 2Q 2022) Aug 13Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price RequirementJul 07Ainos, Inc. Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20 Million Revenue TargetJun 15Ainos, Inc. Announces Chief Financial Officer ChangesMay 18Here's Why Ainos (NASDAQ:AIMD) Can Afford Some DebtMay 15First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2022) May 14Full year 2022 earnings released: US$1.03 loss per share (vs US$0.52 loss in FY 2021) Apr 08Ainos Receives Non-Compliance Notice From NasdaqJan 11Ainos, Inc Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion AnimalsNov 22Third quarter 2022 earnings released: US$0.51 loss per share (vs US$0.12 loss in 3Q 2021) Nov 16Less than half of directors are independent Nov 16Ainos, Inc. Pursues Licensing Partners to Accelerate Five Candidates of Its Low-Dose Oral Interferon Formulation Veldona to Phase 3 Trials and CommercializationNov 01Ainos Announces Positive Results from Additional Preclinical Study of Its Low-Dose Oral Interferon Formulation Against New Variant Virus - OmicronOct 01Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19 Sep 30Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19 Aug 24Second quarter 2022 earnings released: US$0.014 loss per share (vs US$0.09 loss in 2Q 2021) Aug 16Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M Aug 15Ainos, Inc. has completed a Composite Units Offering in the amount of $3.315 million.Aug 10Less than half of directors are independent Aug 09Ainos Announces Positive Results from Preclinical Studies of Its Low-Dose Oral Interferon Formulation Against Covid-19Jun 28Ainos, Inc. Announces Executive ChangesJun 17Ainos, Inc. announced delayed 10-Q filingAug 18財務状況分析短期負債: AIMDの 短期資産 ( $1.1M ) が 短期負債 ( $1.1M ) を超えています。長期負債: AIMDの短期資産 ( $1.1M ) は 長期負債 ( $12.2M ) をカバーしていません。デット・ツー・エクイティの歴史と分析負債レベル: AIMDの 純負債対資本比率 ( 139.9% ) は 高い と見なされます。負債の削減: AIMDは 5 年前には株主資本がマイナスでしたが、現在はプラスになっており、改善されています。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: AIMDは、現在の フリーキャッシュフロー に基づくと、キャッシュランウェイ が 1 年未満です。キャッシュランウェイの予測: AIMDは、フリーキャッシュフローが毎年31.7 % の歴史的率で減少し続ける場合、キャッシュランウェイが 1 年未満になります。健全な企業の発掘7D1Y7D1Y7D1YTech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/01 03:42終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ainos, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)Jul 20
Ainos, Inc. Announces Institutional Review Board Approval for Sjögren’S Syndrome Clinical StudyNov 12
Ainos, Inc. Advances Healthcare and Industrial Innovations with AI Nose and VELDONA TechnologiesOct 08
Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for HIV-Oral Warts Clinical TrialSep 26
Ainos Announces Plan to Initiate Taiwan Clinical Study for Veldona as Potential Treatment of Oral Warts in HIV-Positive PatientsSep 18
Ainos, Inc. Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing SafetyAug 20
Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)Jul 20
Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDAJun 15
Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential MarketMay 16
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 SymptomsFeb 05
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of SmellDec 26
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate SecretaryDec 23
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDANov 22
Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price RequirementJul 07
Ainos, Inc. Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20 Million Revenue TargetJun 15
Ainos, Inc Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion AnimalsNov 22
Ainos, Inc. Pursues Licensing Partners to Accelerate Five Candidates of Its Low-Dose Oral Interferon Formulation Veldona to Phase 3 Trials and CommercializationNov 01
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-Dose Oral Interferon Formulation Against New Variant Virus - OmicronOct 01
Ainos Announces Positive Results from Preclinical Studies of Its Low-Dose Oral Interferon Formulation Against Covid-19Jun 28